Val-Ala-PABC-Exatecan

• UNSPSC Description:

  Val-Ala-PABC-Exatecan is a Drug-Linker Conjugates for ADC，consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor，HY-13631). Val-Ala-PABC-Exatecan can be used for ADC molecues synthesis，such as Mal-PEGn-amide-va-Exatecan[1].

• Target Antigen:

  Drug-Linker Conjugates for ADC; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/val-ala-pabc-exatecan.html

• Solubility:

  DMSO : 200 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CC[C@]1(C(OCC2=C1C=C3C4=NC5=CC(F)=C(C6=C5C([C@H](CC6)NC(OCC7=CC=C(C=C7)NC([C@@H](NC([C@H](C(C)C)N)=O)C)=O)=O)=C4CN3C2=O)C)=O)O

• Molecular Weight:

  754.80

• References & Citations:

  [1]Cheng X, et al. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  2845164-91-0